{
  "@context": ["file://domain/_contexts/base.jsonld", "file://domain/_contexts/medicine.jsonld"],
  "@type": ["EducationalResource", "MedicalEntity"],
  "@id": "vascular:venous:svt-001-definition",
  "metadata": {
    "version": "2.0.0",
    "created": "2026-01-05T02:58:00.000Z",
    "contributors": ["copilot-agent", "copilot-agent", "knowledge-graph-agent"],
    "confidence": 0.95,
    "status": "validated",
    "last_updated": "2026-01-06T17:30:00.000Z"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pathology/venous",
    "type": "concept",
    "difficulty": "intermediate",
    "importance": "critical",
    "aku_id": "SVT-001",
    "keywords": ["superficial thrombophlebitis", "SVT", "venous thrombosis", "SFJ proximity", "anticoagulation"],
    "medical_specialty": "vascular_surgery",
    "clinical_context": "venous_disease"
  },
  "content": {
    "statement": {
      "text": "Superficial venous thrombophlebitis (SVT) is thrombosis and inflammation of a superficial vein, characterized by a painful erythematous palpable cord. Critical management decisions depend on proximity to the deep system: thrombus within 3-5cm of the SFJ or SPJ requires anticoagulation due to high DVT/PE risk, and 6-40% of SVT patients have concurrent DVT at presentation.",
      "formal": "SVT_Management: Proximity_to_SFJ < 3-5cm â†’ Anticoagulation; DVT_Coexistence: 6-40%; PE_Risk if untreated near junction: 3-4%"
    },
    "explanation": {
      "intuition": "SVT is like a small fire in a peripheral building - it's usually contained and self-limited. But if it's spreading toward the main building (deep venous system), you need to act aggressively to prevent it from becoming a much bigger problem. The closer to the SFJ, the greater the risk.",
      "key_insight": "The old teaching that 'superficial phlebitis is just phlebitis' is dangerous. SVT is a marker of hypercoagulability and often occurs with concurrent DVT. ALWAYS ultrasound to check for DVT and assess proximity to deep system. Treatment escalates dramatically based on location.",
      "technical_details": "SVT affects 3-11% of the population, usually in association with varicose veins (60-80%). The CALISTO trial showed fondaparinux 2.5mg daily for 45 days reduces DVT/PE risk by 85% in SVT patients. Anticoagulation is indicated when thrombus is within 3-5cm of the SFJ or SPJ, when thrombus is >5cm long, or when there's no obvious provocation (suggesting hypercoagulability). The SURPRISE trial confirmed that rivaroxaban 10mg is also effective for high-risk SVT.",
      "common_misconceptions": [
        "Misconception: SVT is a benign condition needing only local care. Reality: 6-40% have concurrent DVT; 3-4% progress to PE if near junction.",
        "Misconception: Clinical exam is sufficient for SVT diagnosis. Reality: Ultrasound is mandatory to assess extent and exclude DVT.",
        "Misconception: Antibiotics are needed for SVT. Reality: Unless septic, SVT is inflammatory not infectious - use NSAIDs, not antibiotics."
      ]
    }
  },
  "clinical_features": {
    "epidemiology": {
      "incidence": "3-11% of population",
      "peak_age": "4th-6th decades",
      "associations": [
        "Varicose veins (60-80%)",
        "IV catheter use",
        "Malignancy (Trousseau syndrome)",
        "Pregnancy/postpartum",
        "Hypercoagulable states",
        "Hormone therapy"
      ],
      "dvt_association": "6-40% have concurrent DVT at presentation"
    },
    "pathophysiology": {
      "mechanism": "Virchow's triad: endothelial injury, stasis, hypercoagulability",
      "locations": {
        "gsv_system": "Most common - GSV and tributaries (70%)",
        "ssv_system": "Small saphenous vein (15%)",
        "upper_extremity": "Often catheter-related (15%)"
      },
      "extension_risk": "Thrombus may propagate to deep system through SFJ or SPJ"
    },
    "classification": {
      "spontaneous": "Associated with varicose veins, hypercoagulability",
      "iatrogenic": "IV catheter, PICC line, infusion-related",
      "migratory": "Thrombophlebitis migrans - changing locations (malignancy marker)",
      "septic": "Infected thrombus, fever, purulence - usually catheter-related"
    },
    "presentation": [
      "Erythema, warmth, tenderness along superficial vein",
      "Palpable cord (firm linear mass following vein)",
      "Localized pain worse with palpation",
      "Usually no systemic symptoms (unless septic)"
    ],
    "diagnosis": [
      "Clinical examination (palpable tender cord)",
      "Duplex ultrasound (REQUIRED) - assess extent, exclude DVT",
      "Measure proximity to SFJ/SPJ (critical for treatment)",
      "Evaluate deep system for concurrent DVT",
      "Consider malignancy workup if unprovoked or migratory"
    ],
    "treatment": {
      "risk_stratification": {
        "low_risk": "Isolated, <5cm, distal location, catheter-related",
        "high_risk": "Within 3-5cm of SFJ/SPJ, >5cm length, unprovoked, bilateral, recurrent"
      },
      "low_risk_svt": [
        "NSAIDs for pain and inflammation",
        "Warm compresses",
        "Compression therapy",
        "Ambulation encouraged",
        "Follow-up duplex in 1-2 weeks"
      ],
      "high_risk_svt": [
        "Anticoagulation for 4-6 weeks",
        "Fondaparinux 2.5mg daily (CALISTO trial) OR",
        "Rivaroxaban 10mg daily (SURPRISE trial) OR",
        "LMWH prophylactic dose",
        "Compression and ambulation"
      ],
      "thrombus_at_junction": [
        "Therapeutic anticoagulation as for DVT",
        "Consider SFJ/SPJ ligation if progressing despite anticoagulation"
      ],
      "septic_svt": [
        "IV antibiotics",
        "Remove catheter or infected source",
        "Possible surgical drainage",
        "Consider anticoagulation"
      ]
    },
    "key_trials": {
      "calisto": "Fondaparinux 2.5mg daily x 45 days reduces DVT/PE by 85%",
      "surprise": "Rivaroxaban 10mg effective for high-risk SVT"
    }
  },
  "skos": {
    "prefLabel": {
      "@language": "en",
      "@value": "Superficial Venous Thrombophlebitis"
    },
    "altLabel": [
      "SVT",
      "Superficial phlebitis",
      "Superficial thrombophlebitis",
      "Phlebitis"
    ],
    "definition": {
      "@language": "en",
      "@value": "Thrombosis and inflammation of a superficial vein characterized by a painful erythematous palpable cord, requiring ultrasound evaluation and anticoagulation when proximal to the deep venous system."
    },
    "notation": "SVT-001"
  },
  "relationships": {
    "prerequisites": [
      "vascular:venous:ven-001-hemodynamics"
    ],
    "enables": [
      "vascular:venous:dvt-diagnosis",
      "vascular:venous:anticoagulation-decision"
    ],
    "skos:broader": ["vascular:venous:thrombosis"],
    "skos:related": ["vascular:venous:dvt", "vascular:venous:varicose-veins", "vascular:venous:pe"],
    "skos:narrower": []
  },
  "provenance": {
    "sources": [
      {
        "type": "journal",
        "title": "NEJM",
        "article": "CALISTO Trial: Fondaparinux for SVT",
        "year": 2010
      },
      {
        "type": "journal",
        "title": "Lancet Haematology",
        "article": "SURPRISE Trial: Rivaroxaban for SVT",
        "year": 2017
      },
      {
        "type": "textbook",
        "title": "Rutherford's Vascular Surgery",
        "edition": "10th",
        "year": 2023
      }
    ]
  },
  "pedagogical": {
    "target_audience": ["vascular surgery residents", "emergency physicians", "internal medicine residents"],
    "estimated_time": "15min",
    "learning_objectives": [
      "Distinguish SVT from DVT clinically",
      "Identify high-risk features requiring anticoagulation",
      "Describe the essential role of duplex ultrasound in SVT evaluation",
      "Apply treatment algorithm based on thrombus location and extent"
    ],
    "clinical_pearls": [
      "ALWAYS perform duplex ultrasound - 6-40% have concurrent DVT",
      "Thrombus within 3-5cm of SFJ/SPJ requires anticoagulation",
      "Migratory thrombophlebitis (Trousseau syndrome) is a marker of occult malignancy",
      "CALISTO: Fondaparinux 2.5mg daily x 45 days reduces DVT/PE by 85%",
      "Remove IV catheters but always ultrasound to assess thrombus extent"
    ],
    "board_yield": "HIGH"
  },
  "medicalCode": [
    {
      "codingSystem": "SNOMED-CT",
      "codeValue": "64156001",
      "description": "Thrombophlebitis of superficial vein"
    },
    {
      "codingSystem": "ICD-10-CM",
      "codeValue": "I80.00",
      "description": "Phlebitis and thrombophlebitis of superficial vessels of unspecified lower extremity"
    },
    {
      "codingSystem": "ICD-10-CM",
      "codeValue": "I80.10",
      "description": "Phlebitis and thrombophlebitis of femoral vein"
    }
  ]
}
